Evidence map›Paper›PMID 39237967›Full record

ArticleBiology direct2024

GALNT9 enrichment attenuates MPP

Yuanwen Peng, Jun Liu, Lili Sun, Qiuying Zheng, Can Cao, Wenyong Ding, Shufeng Yang, Li Ma, Wenli Zhang

Abstract read
In one paragraph

Article in Biology direct, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. The Critical Role of GALNTs-Regulated O-GalNAc Glycosylation in Cancer Malignancy.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuanwen Peng *Department of Epidemiology, Dalian Medical University, Dalian, 116044, China.
Jun Liu *Department of Epidemiology, Dalian Medical University, Dalian, 116044, China.
Lili SunBiochemistry and Molecular Biology Department of College of Basic Medical Sciences, Dalian Medical University, Dalian, 116044, China.
Qiuying ZhengDepartment of Epidemiology, Dalian Medical University, Dalian, 116044, China.
Can CaoDepartment of Epidemiology, Dalian Medical University, Dalian, 116044, China.
Wenyong DingBiochemistry and Molecular Biology Department of College of Basic Medical Sciences, Dalian Medical University, Dalian, 116044, China.
Shufeng YangDepartment of Microbiology, Dalian Medical University, Dalian, 116044, China.
Li MaDepartment of Epidemiology, Dalian Medical University, Dalian, 116044, China. mali_lele@sina.com.
Wenli ZhangBiochemistry and Molecular Biology Department of College of Basic Medical Sciences, Dalian Medical University, Dalian, 116044, China. zhangwenli@dmu.edu.cn.

Funding

Applied Basic Research Project of Liaoning Province 2022JH2/101300084
6 · The paper itself

Abstract

backgroundGALNTs (UDP-GalNAc; polypeptide N-acetylgalactosaminyltransferases) initiate mucin-type O-GalNAc glycosylation by adding N-GalNAc to protein serine/threonine residues. Abnormalities in O-GalNAc glycosylation are involved in various disorders such as Parkinson's disease (PD), a neurodegenerative disorder. GALNT9 is potentially downregulated in PD patients.

methodsTo determine whether GALNT9 enrichment ameliorates cytotoxicity related to PD-like variations, a pcDNA3.1-GALNT9 plasmid was constructed and transfected into SH-SY5Y cells to establish a GALNT9-overexpressing cell model.

resultsDownregulation of GALNT9 and O-GalNAc glycosylation was confirmed in our animal and cellular models of PD-like variations. GALNT9 supplementation greatly attenuated cytotoxicity induced by MPP

conclusionsGALNT9 enrichment improved cell survival, and glial GALNT9 potentially represents a pathogenic index for PD patients. This study provides insights into the development of therapeutic strategies for the treatment of PD.

Indexed as

1-Methyl-4-phenylpyridiniumalpha-SynucleinMitochondriaN-AcetylgalactosaminyltransferasesPolypeptide N-acetylgalactosaminyltransferaseAnimalsApoptosisCell Line, TumorGlycosylationHumansMaleMembrane Potential, MitochondrialMiceParkinson DiseaseProtein AggregatesReactive Oxygen Species1-Methyl-4-phenylpyridiniumalpha-SynucleinN-AcetylgalactosaminyltransferasesPolypeptide N-acetylgalactosaminyltransferaseProtein AggregatesReactive Oxygen SpeciesGALNTGlycosylationMitochondrial dysfunctionParkinson’s diseaseΑ-synuclein

Identifiers

PMID39237967
PMCPMC11378468

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.